168 related articles for article (PubMed ID: 37418682)
1. Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
Sun LF; Maples KT; Hall KH; Liu Y; Cao Y; Joseph NS; Hofmeister CC; Kaufman JL; Dhodapkar M; Nooka AK; Lonial S; Harvey RD
JCO Oncol Pract; 2023 Sep; 19(9):793-798. PubMed ID: 37418682
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138
[TBL] [Abstract][Full Text] [Related]
3. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.
Kumar SK; Laubach JP; Giove TJ; Quick M; Neuwirth R; Yung G; Rajkumar SV; Richardson PG
Br J Haematol; 2017 Sep; 178(5):756-763. PubMed ID: 28591409
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials.
Li T; Timmins HC; King T; Kiernan MC; Goldstein D; Park SB
Hematol Oncol; 2020 Aug; 38(3):229-243. PubMed ID: 31873944
[TBL] [Abstract][Full Text] [Related]
5. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
Cavaletti G; Jakubowiak AJ
Leuk Lymphoma; 2010 Jul; 51(7):1178-87. PubMed ID: 20497001
[TBL] [Abstract][Full Text] [Related]
6. Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.
Hashimoto N; Yokoyama K; Sadahira K; Ueda T; Tsukada Y; Okamoto S
Int J Hematol; 2012 Dec; 96(6):758-63. PubMed ID: 23179905
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced motor neuropathy: A case report.
Singh M; Thomas VM; Mulay S
J Oncol Pharm Pract; 2020 Sep; 26(6):1549-1552. PubMed ID: 32054409
[TBL] [Abstract][Full Text] [Related]
8. Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma.
Moore DC; Ringley JT; Nix D; Muslimani A
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):168-173. PubMed ID: 32029398
[TBL] [Abstract][Full Text] [Related]
9. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.
Yan W; Wu Z; Zhang Y; Hong D; Dong X; Liu L; Rao Y; Huang L; Zhang X; Wu J
Biomed Pharmacother; 2021 Oct; 142():112068. PubMed ID: 34463262
[TBL] [Abstract][Full Text] [Related]
10. Therapy-related peripheral neuropathy in multiple myeloma patients.
Morawska M; Grzasko N; Kostyra M; Wojciechowicz J; Hus M
Hematol Oncol; 2015 Dec; 33(4):113-9. PubMed ID: 25399783
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
Argyriou AA; Iconomou G; Kalofonos HP
Blood; 2008 Sep; 112(5):1593-9. PubMed ID: 18574024
[TBL] [Abstract][Full Text] [Related]
12. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
Wang J; Udd KA; Vidisheva A; Swift RA; Spektor TM; Bravin E; Ibrahim E; Treisman J; Masri M; Berenson JR
Support Care Cancer; 2016 Jul; 24(7):3105-10. PubMed ID: 26902977
[TBL] [Abstract][Full Text] [Related]
13. Prediction of bortezomib-induced peripheral neuropathy with the R-R interval variation of the electrocardiogram in plasma cell myeloma: a retrospective study.
Nishiwaki U; Yokote T; Hatooka J; Miyoshi T; Iwaki K; Masuda Y; Fujimoto M; Ueda M; Kinoshita Y; Arita Y; Shimizu M; Yamada T; Tanabe K; Akioka T; Imagawa A
Leuk Lymphoma; 2020 Mar; 61(3):707-713. PubMed ID: 31642372
[TBL] [Abstract][Full Text] [Related]
14. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
15. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Velasco R; Petit J; Clapés V; Verdú E; Navarro X; Bruna J
J Peripher Nerv Syst; 2010 Mar; 15(1):17-25. PubMed ID: 20433602
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy.
Lee SE; Choi K; Han S; Lee J; Hong T; Park GJ; Yim DS; Min CK
Anticancer Drugs; 2017 Jul; 28(6):660-668. PubMed ID: 28430745
[TBL] [Abstract][Full Text] [Related]
17. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.
Koh Y; Lee SY; Kim I; Kwon JH; Yoon SS; Park S; Chung MH; Suh SY; Kim KS; Kim HS
Cancer Chemother Pharmacol; 2014 Sep; 74(3):653-7. PubMed ID: 25096796
[TBL] [Abstract][Full Text] [Related]
19. [Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].
Zhang LL; Wang YH; Shao ZH; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):480-484. PubMed ID: 28446297
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
